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A New Target for Amyloid Beta Toxicity Validated by
Standard and High-Throughput Electrophysiology
Kucku Varghese1,2, Peter Molnar1, Mainak Das1, Neelima Bhargava1, Stephen Lambert1,3, Mark S.
Kindy2, James J. Hickman1,2*
1 NanoScience Technology Center, University of Central Florida, Orlando, Florida, United States of America, 2 Department of Neuroscience, Medical University of South
Carolina, Charleston, South Carolina, United States of America, 3 College of Medicine, University of Central Florida, Orlando, Florida, United States of America

Abstract
Background: Soluble oligomers of amyloid beta (Ab) are considered to be one of the major contributing factors to the
development of Alzheimer’s disease. Most therapeutic development studies have focused on toxicity directly at the
synapse.
Methodology/Principal Findings: Patch clamp studies detailed here have demonstrated that soluble Ab can also cause
functional toxicity, namely it inhibits spontaneous firing of hippocampal neurons without significant cell death at low
concentrations. This toxicity will eventually lead to the loss of the synapse as well, but may precede this loss by a
considerable amount of time. In a key technological advance we have reproduced these results utilizing a fast and simple
method based on extracellular electrophysiological recording of the temporal electrical activity of cultured hippocampal
neurons using multielectrode arrays (MEAs) at low concentrations of Ab (1–42). We have also shown that this functional
deficit can be reversed through use of curcumin, an inhibitor of Ab oligomerization, using both analysis methods.
Conclusions/Significance: The MEA recording method utilized here is non-invasive, thus long term chronic measurements
are possible and it does not require precise positioning of electrodes, thus it is ideal for functional screens. Even more
significantly, we believe we have now identified a new target for drug development for AD based on functional toxicity of
hippocampal neurons that could treat neurodegenerative diseases prior to the development of mild cognitive impairment.
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Although it is well known that one of the early hallmarks of AD
is marked synaptic degeneration, its cause is only marginally
understood [8,9]. According to the leading theory, soluble oligomers
of Ab have a direct ‘‘synaptotoxic’’ effect at nanomolar concentrations [10,11]. Other authors have emphasized the success of
Memantine, an NMDA antagonist, in moderate and severe cases of
AD, and claim that excitotoxicity could play a role in synaptic
degeneration [12–14]. Our hypothesis is based on the observation
that Ab decreases spontaneous activity of neurons at low
concentrations and that this has a deleterious effect on cell
functionality without significant cell death. According to established
theories, this decreased activity would lead to the automatic
elimination of synapses with low activity, but at a later time [15,16].
It has also been shown that Ab toxicity can be reversed to varying
degrees using anti-amyloidogenic compounds (AACs) such as
curcumin [17]. Curcumin has been shown to have anti-oxidant
and anti-inflammatory properties [18] and reduce amyloid plaque
burden in transgenic APPsw mice [19]. More recently, curcumin
has been shown to reduce the number of aggregates from
monomeric Ab as well as promote disassembly of preformed Ab
aggregates, in addition to inhibiting Ab oligomer formation and Ab
toxicity at significantly lower concentrations than Ibuprofen [20].

Introduction
We have demonstrated that high-throughput electrophysiology
techniques can be used to measure Amyloid beta (Ab) toxicity in
neurons and that the effects of this toxicity can be reversed by a drug
application. In addition, we believe we have identified a new target
for drug development for Alzheimer’s Disease (AD) that focuses on
loss of electrical functionality of the cell that may precede synapse
degradation by a considerable period of time. These results support
the emerging view that functional impairment of neurons may be
more important for the development of AD symptoms than the
actual cell death which occurs at later stages of the disease [1,2].
AD is the most common cause of dementia in the elderly [3].
The hallmarks of this disease consist of senile plaques composed of
Ab, neurofibrillary tangles and extensive neuronal degeneration
[4]. Ab is a 39–43 amino acid peptide derived from the cleavage of
a larger protein, Amyloid Precursor Protein (APP), and is toxic to
neurons in vivo and in vitro [5]. The amyloid cascade hypothesis
implicates Ab as having a crucial role in the pathogenesis of AD
[6] and as a result is an important therapeutic target. Recent
results have implicated soluble aggregates of Ab for many of the
toxic effects of Ab described in AD [7].
PLoS ONE | www.plosone.org
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cells. No significant changes in the baseline recordings from
control MEAs were observed as a result of transferring the MEAs
from the incubator to the recording headstage or media changes.

Most in vitro functional electrophysiological studies on the effects
of Ab on neurons have been carried out using the patch clamp
method [2,21,22]. Although the use of this technique enables the
acquisition of detailed information concerning Ab effects at the ion
channel level, it is very low throughput and complicated relative to
extracellular electrophysiological techniques. A recent technological advance for non-invasive chronic monitoring of neuronal and
cardiac cell electrical activity is the use of multielectrode array
(MEA) recordings of action potentials [23–27]. In contrast to the
more common intracellular electrophysiological techniques which
usually enable only short term (,a few hours) monitoring of the
activity of cells, MEAs are ideal for investigating long-term/
chronic drug effects and also does not limit the number of cells that
can be recorded from, at a single instance [24,26,28–30].
Moreover, because MEAs do not require precise positioning of
electrodes, they can be used in high-throughput pharmaceutical
screens [31]. The most common applications of MEAs include
physiological or pharmacological studies in brain slices and in
dissociated cell cultures of electrogenic cells including hippocampal neurons [32,33], spinal cord neurons [34] and cardiac
myocytes [24,25], among others. Recent developments in the
pharmacological applications of MEA technology [31] have shown
that introduction of high-throughput functional in vitro electrophysiological assays in drug development could have significant
benefits compared to the traditional in vivo or ex vivo assays. For
example, electrophysiologically active in vitro neuronal networks
have been maintained on microelectrode arrays for over 9 months
[34]. More recently, neurons on MEAs have been used to study
various drug effects including antidepressants [35], ACHe
inhibitors [36] and Zn toxicity [37].
In this study we have developed a high-throughput in vitro
method for the assessment of Ab effects on spontaneous activity of
cultured neurons which can be adapted for high-throughput
pharmaceutical screening. This assertion is supported by the
emerging view that functional impairment of neurons might be
more important for the development of AD symptoms than the
actual cell death which occurs at later stages of the disease [1,2].
The results obtained with MEAs correlate well with those obtained
using patch clamp electrophysiology wherein Ab at low concentrations had a deleterious effect on cell functionality without
significant cell death. We have also shown that this effect can be
reversed to varying degrees using an anti-amyloidogenic compound. The MEA recording method utilized here is non-invasive,
thus long term chronic measurements are possible and it does not
require precise positioning of electrodes, thus it is ideal for
functional screens. Even more significantly, we believe we have
now identified a new target for drug development for AD based on
functional toxicity of hippocampal neurons.

Application of Ab Abolished Spontaneous Spiking
Activity
The presence of Ab oligomers was verified using immunoblots
as shown in Figure 1. Patch clamp experiments performed 24 h
post-Ab exposure revealed striking changes in the neuronal
function upon exposure to 100 nM Ab. The most significant
effect was observed on spontaneous firing, namely no spontaneous
action potentials were recorded in the 30 exposed cells that were
studied at the 24 h time point (Figure 2A). Exogenous application
of Ab to the cells for 24 h caused an increase in the amplitude of
the outward (K+) currents as well as a depolarization in the resting
membrane potential, (Figure B,C). Given the small differences in
cell survival compared to the control, even after 7 days (Figure 2D),
we concluded that loss of electrophysiological function is the major
response to Ab treatment at this concentration. To confirm this
finding a MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide) was performed on the amyloid treated cells
and this supported the results obtained with the live dead assay.
As a result of the significant effect of Ab on the firing frequency
of the hippocampal neurons, it was decided to use this parameter
as a possible new target for implementation in high throughput
screens utilizing MEAs. The effect of various concentrations of Ab
on the firing frequency of the neurons on the MEAs that were
studied is shown in Figures 3 and 4. At all measured
concentrations, Ab completely abolishes spontaneous spiking
activity whereas application of the vehicle control had no effect
(Figure 3A). The concentration dependence of Ab action was
quantified by measuring the time required for complete blockade
of spiking activity as the dependent parameter in contrast to a
more traditional concentration/inhibition relationship. When the
cells were exposed to 20 mM Ab, the highest concentration tested,
spiking activity of the cells stopped after about 150 min. At the
lowest concentration (50 nM) the cells stopped firing after about
11 h. As seen in Figure 3B, the time for cessation of spike activity
reached a plateau at around 10 mM at the higher end of the

Results
Embryonic rat neurons were plated at a density of 100 cells/
mm2 on DETA coated coverslips for patch clamp electrophysiology and at 200 cells/mm2 on DETA coated microelectrode
arrays in serum free medium. Patch clamp electrophysiology was
performed after 10 days in culture as electrical function of the
neurons had stabilized at this point. Sporadic firing could also be
detected after 10 days using the MEAs. Starting on day 12 we
were able to obtain stable, reliable recordings from the MEAs over
a period of two to three days with an average firing frequency of
2.560.6 Hz (mean6SEM). This enabled the study of the time
course of the action of low concentrations of Ab on the neurons.
Transferring the MEAs from the incubator to the recording head
stage and subsequent media changes did not significantly affect the
PLoS ONE | www.plosone.org

Figure 1. Immunoblot of Ab oligomers. From left to right: Lane 1 is
the monomer. Lane 2 indicates the apparent inhibition of Ab oligomerization in the presence of Curcumin. Lane 3 indicates Ab oligomers.
doi:10.1371/journal.pone.0008643.g001
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Figure 2. Effect of 24 h exposure to 100 nM Ab on cell functionality measured using whole cell patch clamp electrophysiology.
Changes after exposure to Ab for 24 hr. in spontaneous firing frequency; ***: p = 0.00007 (A), K+ ion channel currents; **: p = 0.008 (B), and membrane
potential; *: p = 0.035 (C). Cell survival after administration of 100 nM Ab at 24 hours and 7 days; *: p = 0.04 (D). Data is presented as mean6SEM;
N = 30 utilizing a two-sample Student’s t-test.
doi:10.1371/journal.pone.0008643.g002

Thus, having demonstrated that Ab functional toxicity could be
reproduced using multielectrode arrays, a screening assay was then
demonstrated by measuring the recovery of the lost functionality
using the anti-amyloidogenic compound curcumin. Based on the
control methodology in Figure 6, two modes of curcumin
application were used. Curcumin was coadministered with Ab to
the cells on the MEAs for a 24 hour period. In the second set of
experiments curcumin was applied sequentially after the cells were
exposed to Ab for 24 hrs. We observed that functional recovery as
recorded by the MEAs was similar to the patch-clamp experiments.
As seen in Figure 7A, when curcumin was coadministered with Ab,
the cells were able to maintain 54.960.7% (mean6SEM) of their
baseline firing activity, as opposed to a complete loss of functionality
when treated with Ab alone. The decline in firing frequency was
more gradual and the drop in firing frequency reached a plateau

concentration range. Blockade of spontaneous activity was
preceded by a significant increase in firing frequency at all
measured concentrations. At high concentrations of Ab, high cell
death was observed as seen in Figure 4. Figure 5 shows the time
course effect of 20 mM Ab on spontaneous firing frequency of the
embryonic hippocampal neurons. These results were in accordance with those obtained using whole cell patch clamp
electrophysiology as indicated in Figure 1.

Partial Functional Activity Could Be Recovered by
Administration of Curcumin
In our patch clamp experiments we determined that low doses
of curcumin (as previously published) were more successful in
ameliorating Ab toxicity when coadministered with Ab as opposed
to administration after 24 h exposure to Ab (Figure 6).

Figure 3. Time course of the effect of Ab on spontaneous activity of cultured embryonic rat hippocampal cells at various
concentrations. Concentrations of 100 nM and 5 mM Ab caused a complete cessation of firing activity with different time delays (N = 5) (A).
Composite logarithmic graph of the time taken for cells to stop firing at the various Ab concentrations tested (B).
doi:10.1371/journal.pone.0008643.g003

PLoS ONE | www.plosone.org
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Figure 4. Ab induced cytotoxicity in hippocampal cells on MEAs. Cell survival before Ab treatment (A) after treatment with 100 nM Ab (B) and
20 uM Ab (C). Green denotes live cells; Red denotes dead cells. Scale bar: 30 mm. Percentage of live cells after treatment with various concentrations
of Ab (D). * p,0.5, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0008643.g004

Ab toxicity is not well known, thus this functional screen could
result in novel effective compounds or therapeutic targets. We
have shown that multielectrode arrays (MEAs) can be used to
reliably detect functional effects of low doses of Ab (100 nM) as
well as screen for the rescue effect of curcumin. When applied to
hippocampal neurons cultured on MEAs Ab had a pronounced
effect on the spontaneous firing of the cells, even at concentrations
in the nanomolar range. Treatment with Ab stopped spontaneous
activity completely and the time for cessation was concentration
dependent. The Ab oligomerization inhibitor, curcumin, was able
to partially reverse the loss of spontaneous activity. In accordance
with our earlier patch clamp experiments, curcumin was more
effective in inhibiting the effect of Ab when it was coadministered
with it as opposed to the experiments in which it was applied
24 hrs after Ab exposure.
Interestingly, after Ab exposure, there was a slight but consistent
increase in firing frequency just before the decline of spontaneous
activity. The initial increase in firing frequency we observed at all
tested Ab concentrations could be due to an earlier reported direct
depolarizing effect of Ab on the membrane potential or to the
reputed ability of Ab to enhance glutamate-mediated excitotoxicity [41,42] by its action on NMDA receptors and consequently,
through an increased influx of Ca2+.
In comparison to slice preparation, our method, measurement
of the effect of Ab on spontaneous activity of cultured neurons, is
significantly simpler and more applicable in high-throughput
screen methodology. Another benefit of this MEA AD model,
compared to our patch-clamp experiments, was that we were able
to follow the time course of the action of curcumin on the Ab
modified activity of the same population of cells. When Ab and
curcumin were applied together, curcumin reduced the deleterious
effect of Ab without a significant change in the time course of Ab
action (Figure 5A). When Ab and curcumin were applied

about 18 hrs after curcumin and Ab were coadministered.
Administration of curcumin after the cells were exposed to Ab for
24 hrs resulted in a gradual recovery of firing frequency to
29.960.7% (mean6SEM) of the baseline (Figure 7B). In this
paradigm, recovery of spontaneous firing was observed around
10 hrs after curcumin was applied post Ab exposure. The recovery
of spontaneous firing frequency obtained with curcumin treatment
was comparable to results obtained with patch clamp electrophysiology using similar experimental paradigms, as shown in Figure 6.

Discussion
Our initial results using whole-cell patch clamp electrophysiology
demonstrated that Ab affects electrical functionality earlier and at
lower concentrations than which affect the survival of the cells. It is
possible this effect could also precede synapse degradation or that it
may be its upstream cause. Previous results had hinted at this idea,
for example Chen and coworkers reported that various low
concentrations of Ab inhibited long-term potentiation (LTP) in
hippocampal slices [2,38,39]. Based on these results, Ahuja et al.
used MEA technology to measure Ab effect on LTP in organotypic
hippocampal cultures [40]. The importance of these investigations is
highlighted by the significant need in the pharmaceutical industry
for an in vitro model of the early stages of Alzheimer disease and the
functional effects of Ab on neurons observed in the study might be
considered as an in vitro AD model.
We then utilized this result to create a high-throughput
screening method for antagonists of this functional toxicity caused
by Ab. The MEAs made it possible to screen a significantly higher
number of cells for Ab and drug effects in a much shorter amount
of time than patch-clamp electrophysiology would have required.
Development of this method could have a high impact on drug
development in Alzheimer’s disease (AD). The molecular target of
PLoS ONE | www.plosone.org
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Figure 5. Time course of the application of 20 uM Ab on spontaneous activity of cultured embryonic rat hippocampal cells on
MEAs. Spontaneous firing observed before administration of 20 uM Ab (A). Spontaneous firing observed 45 minutes after administration of 20 uM
Ab (B), 90 minutes after administration of 20 uM Ab (C) and 150 minutes after administration of 20 uM Ab (D).
doi:10.1371/journal.pone.0008643.g005

sequentially, curcumin reversed the effect of Ab and helped the
cells to partially recover their spontaneous firing activity
(Figure 5A). Curcumin was more effective when administered
together with Ab; the cells were able to retain about 55% of their
firing capability compared to untreated controls when coadministered as opposed to only 30% when sequentially administered. It
has been shown that curcumin was able to inhibit Ab oligomer
formation and reduce amyloid toxicity in vitro [20]. In the presence
of curcumin, reduced aggregation from monomeric Ab and
improved disassembly of preformed Ab aggregates was observed

[20]. Curcumin’s ability to disassemble pre-formed Ab aggregates
could account for its protective effect against Ab toxicity in the coadministration experiments, but the mechanism involved in the
reversal of Ab toxicity in the post-administration experiments
needs further clarification.
In conclusion, this study demonstrated that it is possible to
develop a high-throughput screen for the measurements of drug
effects on functional toxicity of low concentrations of Ab and this
model might be considered as an in vitro functional model of the
development of Alzheimer’s disease. This screen method, based on

Figure 6. Reversal of the effect of Ab by curcumin, measured using whole cell patch clamp electrophysiogy. Curcumin was
coadminstered with Ab or sequentially applied after Ab exposure. The values in Figure 1 were used for baseline comparison. 100% implies complete
reversal of Ab effect and 0% implies no reversal. Effect on firing frequency; ***: p = 0.0007 (A). Effect on potassium currents; **: p = 0.005 (B). Effect on
membrane potential; ***: p = 0.0009, **: p = 0.009 (C). Curcumin treated groups were compared with Ab-only groups using a two-sample Student’s
t-test. Data is presented as mean6SEM.
doi:10.1371/journal.pone.0008643.g006

PLoS ONE | www.plosone.org
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Figure 7. Reversal of the effect of Ab on firing frequency by curcumin applied together with Ab or after Ab exposure. Time course of
the effect of curcumin on spontaneous firing frequency of embryonic hippocampal neurons when coadministered with Ab (N = 5) (A). Time course of
curcumin effect on spontaneous firing frequency of embryonic hippocampal neurons when administered after cells were exposed to Ab for 24 h
(N = 5) (B). 100% implies baseline values before exposure to Ab.
doi:10.1371/journal.pone.0008643.g007

reheated to 70uC, and then oven dried. Surfaces were characterized using contact angle measurement and X-ray photoelectron
spectroscopy (XPS) as described previously [44].

MEA technology, which enables the screening of a large number
of cells, and the study of pathogen and drug effects on the same
population of cells over an extended period of time, could find
important applications in pharmaceutical drug development and
could lead to novel drug candidates or therapies for AD.
Moreover, based on similar principles, MEA technology can be
potentially extended to study in vitro models of other neurodegenerative diseases as well.

Cell Culture
All applied procedures were approved by the Institutional
Animal Care and Use Committee of UCF. The protocol was
modified from previously published work concerning embryonic
rat hippocampal cultures [43,45]. Pregnant rats, 18 days in
gestation, obtained from Charles River were euthanized with
carbon dioxide and the fetuses were collected in ice cold Hibernate
E (BrainBits)/B27/GlutamaxTM/Antibiotic-Antimycotic (Invitrogen) (dissecting medium). Each fetus was decapitated and the
whole brain was transferred to fresh ice cold dissecting medium.
After isolation, the hippocampi were collected in a fresh tube of
dissecting medium. Hippocampal neurons were obtained by
triturating the tissue using a Pasteur pipette. In order to remove
any debris from damaged cells the 1 ml cell suspension was
layered over a 4 ml step gradient (Optipep diluted 0.505: 0.495 (v/
v) with the dissecting medium and then made to 15%, 20%, 25%
and 35% (v/v) in the dissecting medium) followed by centrifugation for 15 min at 800 g and 4uC. After centrifugation, one strong
band of cells was obtained. This band of cells was resuspended in
culture medium (Neurobasal/B27/GlutamaxTM/Antibiotic-Antimycotic) and plated at a density of 100 cells/mm2 on DETA
coated coverslips for patch clamp electrophysiology and at
200 cells/mm2 on the MEAs.

Materials and Methods
Microelectrode Arrays
The MEAs and accompanying accessories, including the
temperature controller, stimulator, amplifier and MC_Rack V
3.5.8 data acquisition software were obtained from ALA Scientific
(Westbury, New York) and Multichannel Systems (Reutlingen,
Germany). The MEAs comprised of a glass base that acted as a
substrate, gold connector contacts and electrodes composed of
titanium nitride. Rings were made of Sylgard184 (Dow Corning)
(1 part curing base and 10 parts elastomer base, cured at 60uC for
45 minutes) using glass molds and were attached onto the MEAs
after surface modification.
Recordings were obtained from 12–16 D. old cultures. Cultures
were kept in the incubator between recording sessions.

Surface Modification
N-1(3-[trimethoxysilyl]propyl)-diethylenetriamine (DETA) was
used to modify the MEAs to enhance cell attachment since the use
of synthetic substrates such as DETA, allows for reproducible and
precise quantification of the culture substrate properties [43].
Glass coverslips (18 mm diameter, Number 1; VWR) were cleaned
in two steps. First, they were soaked in 50/50% HCl (37%)
(VWR)/methanol (Sigma), followed by H2SO4 (98%) (VWR)
treatment. Next, they were rinsed in double distilled water. The
coverslips were then boiled in deionized water, rinsed with
acetone, and oven dried. The MEAs were initially cleaned
overnight in 2% Tergazyme (Sigma) detergent solution. They
were then rinsed in distilled water and plasma cleaned in a plasma
cleaner (Harrick Plasma) for 30 mins. The N-1(3-[trimethoxysilyl]propyl)-diethylenetriamine (DETA) (United Chemical Technologies) surface assembled monolayer (SAM) film was formed by
the reaction of the cleaned surfaces with a 0.1% (v/v) mixture of
the organosilane in toluene. The DETA/toluene solution
containing the MEAs was heated to 70uC, rinsed with toluene,
PLoS ONE | www.plosone.org

Ab (1–42) and Curcumin Administration and
Electrophysiology
Different concentrations of Ab (1–42) (Bachem) aggregates were
prepared according to the protocol by Klein [1] in Neurobasal
medium without phenol red, and quantified using Immunoblots.
Curcumin (Cayman Chemicals) was prepared and the concentration chosen according to previously published protocols [20].
For patch clamp electrophysiology experiments, Ab was
administered to the cells on day 10 in vitro and recordings were
performed after 24 hrs to obtain baseline values for control cells
and Ab treated cells. In coadministration experiments, a mixture
of 100 nM Ab and 1 mM curcumin was administered for 24 hrs
after which patch clamp electrophysiology recordings were
performed. In sequential administration, cells were initially
exposed to freshly aggregated Ab alone, followed by replacement
of the Ab solution with curcumin for 24 hrs patch clamp
6
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recordings were performed 24 hrs after curcumin treatment.
Whole-cell patch clamp recordings were performed at room
temperature in a recording chamber on the stage of a Zeiss
Axioscope 2 FS Plus upright microscope as described in [44].
In all experiments with MEAs Ab was administered to the cells
on day 16 in vitro. We chose experimental paradigms similar to
those used for patch clamp electrophysiology, to study the
potential therapeutic effects of curcumin. In coadministration
experiments, cells were exposed to a mixture of 100 nM Ab and
1 mM Curcumin for 24 hrs, and recordings were performed. In
the second paradigm, cells were initially exposed to freshly
aggregated Ab alone, followed by replacement of the Ab solution
with curcumin for 24 hrs. Extracellular recordings were obtained
before the administration of Ab, immediately after Ab administration, 24 h after Ab administration, before curcumin administration and 24 hrs after curcumin administration.

Cytotoxixity Assays
Using the LIVE/DEADTM viability/cytotoxicity kit (Molecular
Probes), and the MTT based in vitro toxicology assay kit (Sigma),
cell survival was measured as per the instructions that accompanied the kits.

Data Analysis and Statistical Methods
Frequency values for all data points on MEAs were averaged
over 5 MEAs. For patch clamp electrophysiology, a sample size of
N = 30 was used. Changes in parameters induced by all externally
applied chemicals were quantified as a percentage of baseline
values. Statistical significance was calculated used students t test.

Author Contributions
Conceived and designed the experiments: KV MK JJH. Performed the
experiments: KV. Analyzed the data: KV PM SL. Contributed reagents/
materials/analysis tools: MD NB MK. Wrote the paper: KV JJH.

References
1. Klein WL (2002) A beta toxicity in Alzheimer’s disease: globular oligomers
(ADDLs) as new vaccine and drug targets. Neurochemistry International 41(5):
345–352.
2. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998)
Diffusible, nonfibrillar ligands derived from A beta(1–42) are potent central
nervous system neurotoxins. Proceedings of the National Academy of Sciences of
the United States of America 95(11): 6448–6453.
3. St George-Hyslop PH, Petit A (2005) Molecular biology and genetics of
Alzheimer’s disease. Comptes Rendus Biologies 328(2): 119–130.
4. Townsend KP, Pratico D (2005) Novel therapeutic opportunities for Alzheimer’s
disease: focus on nonsteroidal anti-inflammatory drugs. Faseb Journal 19(12):
1592–1601.
5. Yankner BA (1996) Mechanisms of neuronal degeneration in Alzheimer’s
disease. Neuron 16(5): 921–932.
6. Hardy J, Selkoe DJ (2002) Medicine - The amyloid hypothesis of Alzheimer’s
disease: Progress and problems on the road to therapeutics. Science 297(5580):
353–356.
7. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008)
Amyloid-[beta] protein dimers isolated directly from Alzheimer’s brains impair
synaptic plasticity and memory Nature Medicine 14(8): 837–842.
8. Knobloch M, Mansuy IM (2008) Dendritic spine loss and synaptic alterations in
Alzheimer’s disease. Molecular Neurobiology 37(1): 73–82.
9. Lacor PN (2007) Advances on the understanding of the origins of synaptic
pathology in AD. Current Genomics 8(8): 486–508.
10. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, et al. (2007)
Neurobiology of Disease Ab Oligomer-Induced Aberrations in Synapse
Composition, Shape, and Density Provide a Molecular Basis for Loss of
Connectivity in Alzheimer’s Disease. Journal of Neuroscience Methods 27(4):
796–807.
11. Walsh DM, Selkoe DJ (2007) Ab Oligomers – a decade of discovery Journal of
Neurochemistry 101: 1172–1184.
12. Francis PT (2008) Glutamatergic approaches to the treatment of cognitive and
behavioural symptoms of Alzheimer’s disease. Neurodegenerative Diseases 5(3–
4): 241–243.
13. Koike T, Yang Y, Suzuki K, Zheng X (2008) Axon & dendrite degeneration: its
mechanisms and protective experimental paradigms. Neurochem Internat 52(4–
5): 751–760.
14. Waataja JJ, Kim HJ, Roloff AM, Thayer SA (2008) Excitotoxic loss of postsynaptic sites is distinct temporally and mechanistically from neuronal death
ournal of Neurochemistry 104(2): 364–375.
15. Hua JY, Smith SJ (2004) Neural activity and the dynamics of central nervous
system development. Nature Neuroscience 7: 327–332.
16. Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, et al. (2008)
Amyloid b oligomers (A b (1–42) globulomer) suppress spontaneous synaptic
activity by inhibition of P/Q-type calcium currents Journal of Neuroscience
Methods 28(4): 788–797.
17. Hamaguchi T, Ono K, Yamada M (2006) Anti-amyloidogenic therapies:
strategies for prevention and treatment of Alzheimer’s disease. Cellular and
Molecular Life Sciences 63(13): 1538–1552.
18. Zhao BL, Li XJ, He RG, Cheng SJ, Xin WJ (1989) Scavenging Effect of Extracts
of Green Tea and Natural Antioxidants on Active Oxygen Radicals. Cell
Biophysics 14(2): 175–185.
19. Lim GP, Chu T, Yang FS, Beech W, Frautschy SA, et al. (2001) The curry spice
curcumin reduces oxidative damage and amyloid pathology in an Alzheimer
transgenic mouse. Journal of Neuroscience 21(21): 8370–8377.
20. Yang FS, Lim GP, Begum AN, Ubeda OJ, Simmons MR, et al. (2005)
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds

PLoS ONE | www.plosone.org

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.
33.

34.

35.

36.

37.
38.

7

plaques, and reduces amyloid in vivo. Journal of Biological Chemistry 280(7):
5892–5901.
Gureviciene I, Ikonen S, Gureviclus K, Sarkaki A, van Groen T, et al. (2004)
Normal induction but accelerated decay of LTP in APP+PS1 transgenic mice.
Neurobiology of Disease 15(2): 188–195.
Jhamandas JH, Cho C, Jassar B, Harris K, MacTavish D, et al. (2001) Cellular
mechanisms for amyloid beta-protein activation of rat cholinergic basal
forebrain neurons. Journal of Neurophysiology 86(3): 1312–1320.
Egert U, Schlosshauer B, Fennrich S, Nisch W, Fejtl M, et al. (1998) A novel
organotypic long-term culture of the rat hippocampus on substrate-integrated
multielectrode arrays. Brain Research Protocols 2(4): 229–242.
Jung DR, Cuttino DS, Pancrazio JJ, Manos P, Cluster T, et al. (1998) Cell-based
sensor microelectrode array characterized by imaging x-ray photoelectron
spectroscopy, scanning electron microscopy, impedance measurements, and
extracellular recordings. Journal of Vacuum Science & Technology a-Vacuum
Surfaces and Films 16(3): 1183–1188.
Natarajan A, Molnar P, Sieverdes K, Jamshidi A, Hickman JJ (2006)
Microelectrode array recordings of cardiac action potentials as a high throughput
method to evaluate pesticide toxicity. Toxicology in Vitro 20(3): 375–381.
Offenhausser A, Sprossler C, Matsuzawa M, Knoll W (1997) Field-effect
transistor array for monitoring electrical activity from mammalian neurons in
culture. Biosensors & Bioelectronics 12(8): 819–826.
Nam Y, Wheeler BC, Heuschkel MO (2006) Neural recording adn stimulation
of dissociated hippocampal cultures using microfabricated three-dimensional tip
electrode array. Journal of Neuroscience Methods 155(2): 296–299.
Hofmann F, Bading H (2006) Long term recordings with microelectrode arrays:
Studies of transcription-dependent neuronal plasticity and axonal regeneration.
Journal of Physiology-Paris 99(2–3): 125–132.
Thomas CA, Springer PA, Okun LM, Berwaldn Y, Loeb GE (1972) Miniature
Microelectrode Array to Monitor Bioelectric Activity of Cultured Cells.
Experimental Cell Research 74(1): 61–&.
Gross GW, Gramowski A, Schiffmann D (1997) Neural network cultures on
multielectrode chips: Self-organization of electrically active networks and their
uses in neurotoxicology and neuropharmacology. European Journal of Cell
Biology 74: 36–36.
Meyer T, Boven KH, Gunther E, Fejtl M (2004) Micro-electrode arrays in
cardiac safety pharmacology - A novel tool to study QT interval prolongation.
Drug Safety 27(11): 763–772.
Chang JC, Brewer GJ, Wheeler BC (2001) Modulation of neural network
activity by patterning. Biosensors & Bioelectronics 16(7–8): 527–533.
Golan H, Mikenberg K, Greenberger V, Segal M (2000) GABA withdrawal
modifies network activity in cultured hippocampal neurons. Neural Plasticity
7(1–2): 31–42.
Gross GW, Rhoades BK, Azzazy HME, Wu MC (1995) The Use of Neuronal
Networks on Multielectrode Arrays as Biosensors. Biosensors & Bioelectronics
10(6–7): 553–567.
Gramowski A, Jugelt K, Stuwe S, Schulze R, McGregor GP, et al. (2006)
Functional screening of traditional antidepressants with primary cortical
neuronal networks grown on multielectrode neurochips. European Journal of
Neuroscience 24(2): 455–465.
Keefer EW, Norton SJ, Boyle NAJ, Talesa V, Gross GW (2001) Acute toxicity
screening of novel AChE inhibitors using neuronal networks on microelectrode
arrays. Neurotoxicology 22(1): 3–12.
Parviz M, Gross GW (2007) Quantification of zinc toxicity using neuronal
networks on microelectrode arrays. Neurotoxicology 28(3): 520–531.
Chen QS, Kagan BL, Hirakura Y, Xie CW (2000) Impairment of hippocampal
long-term potentiation by Alzheimer amyloid beta-peptides. Journal of
Neuroscience Research 60(1): 65–72.

January 2010 | Volume 5 | Issue 1 | e8643

New Target for AB Toxicity

39. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, et al. (2002) Soluble
oligomers of beta amyloid (1–42) inhibit long-term potentiation but not longterm depression in rat dentate gyrus. Brain Research 924(2): 133–140.
40. Ahuja TK, Mielke JG, Comas T, Chakravarthy B, Mealing GAR (2007)
Hippocampal slice cultures integrated with multi-electrode arrays: A model for
study of long-term drug effects on synaptic activity. Drug Development Research
68(2): 84–93.
41. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor
blockade: Memantine and beyond. Nature Reviews Drug Discovery 5(2):
160–170.
42. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, et al. (1992) BetaAmyloid Peptides Destabilize Calcium Homeostasis and Render Human

PLoS ONE | www.plosone.org

Cortical-Neurons Vulnerable to Excitotoxicity. Journal of Neuroscience 12(2):
376–389.
43. Schaffner AE, Barker JL, Stenger DA, Hickman JJ (1995) Investigation of the
factors necessary for growth of hippocampal neurons in a defined system.
Journal of Neuroscience Methods 62(1–2): 111–119.
44. Das M, Molnar P, Devaraj H, Poeta M, Hickman JJ (2003) Electrophysiological
and morphological characterization of rat embryonic motoneurons in a defined
system. Biotechnology Progress 19(6): 1756–1761.
45. Brewer GJ, Torricelli JR, Evege EK, Price PJ (1993) Optimized Survival of
Hippocampal-Neurons in B27-Supplemented Neurobasal(Tm), a New SerumFree Medium Combination. Journal of Neuroscience Research 35(5): 567–576.

8

January 2010 | Volume 5 | Issue 1 | e8643

